Resources
- EGFR-Directed ADCs for Cancer Treatment
- Kadcyla - Top-Selling Antibody Drug Conjugate (ADC)
- Blockbuster Drugs Approved by the FDA in August 2020
- Overviews of the Antibody-drug conjugates (ADCs)
- ADCs Beyond Cancer: Emerging Therapeutic Potential
- ADC Market 2025: Rising Sales and Growing Phase III Pipelines
- Antibody-Degrader Conjugates (DACs): The Next Evolution of Antibody-Drug Conjugates
- The Rise of the TROP2-Directed ADCs for Solid Tumors
- Antibody–Drug Conjugates Targeting MUC1
- Global Sales of ADCs in 2023 – UP to 10 Billion
